Ovarian cancer stem cells

Neoplasma

Volumn 59, Issue 6, 2012, Pages 747-755

  Zeimet, A G ^a   Reimer, D ^a   Sopper, S ^a,b   Boesch, M ^a,b   Martowicz, A ^c   Roessler, J ^a   Wiedemair, A M ^a   Rumpold, H ^d   Untergasser, G ^c   Concin, N ^a   Hofstetter, G ^a   Mueller Holzner, E ^a   Fiegl, H ^a   Marth, C ^a   Wolf, D ^a,e   Pesta M ^f   Hatina, J ^f  

^a Department of Obstetrics and Gynecology ^*  (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Klinikum der Barmherzigen Schwestern Linz   (Austria)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ERCC1; Flow cytometry; Mesothelium co culture; Ovarian cancer; Side population; Stem cell

Indexed keywords

ALDEHYDE DEHYDROGENASE; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CISPLATIN; ELACRIDAR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FUMITREMORGIN C; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM; RESERPINE; STEM CELL FACTOR RECEPTOR; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

CANCER STEM CELL; CANCER TRANSPLANTATION; HUMAN; NONHUMAN; OVARY CANCER; REVIEW; SIDE POPULATION CELL; ANIMAL; CELL SEPARATION; COCULTURE; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL SEPARATION; COCULTURE TECHNIQUES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDONUCLEASES; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS;

EID: 84872676923     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_094     Document Type: Review

References (39)

1. POSTE G, GREIG R. On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 1982; 2: 137-176.
2. POSTE G, TZENG J, DOLL J, GREIG R, RIEMAN D et al. Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc. Natl. Acad. Sci. USA 1982; 79: 6574-6578. http://dx.doi.org/10.1073/pnas.79.21.6574
3. REYA T, MORRISON SJ, CLARKE MF, WEISSMAN IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. http://dx.doi.org/10.1038/35102167
4. TU SM, LIN SH, LOGOTHETIS CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002; 38: 508-513. http://dx.doi.org/10.1016/S1470-2045(02)00820-3
5. ZHANG S, BALCH C, CHAN MW, LAI HC, MATEI D et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68: 4311-4320. http://dx.doi.org/10.1158/0008-5472.CAN-08-0364
6. PONNUSAMY MP, BATRA SK. Ovarian cancer: emerging concept on cancer stem cells. J. Ovarian Res. 2008; 1: 4. http://dx.doi.org/10.1186/1757-2215-1-4
7. FONG MY, KAKAR SS. The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol. Histopathol. 2010; 25, 113-120.
8. GAO MQ, CHOI YP, KANG S, YOUN JH, CHO NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29: 2672-2680. http://dx.doi.org/10.1038/onc.2010.35
9. DENG S, YANG X, LASSUS H, LIANG S, KAUR S, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010; 5: e10277. http://dx.doi. org/10.1371/journal.pone.0010277
10. YANG K, CHEN XZ, ZHANG B, YANG C, CHEN HN et al. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int. J. Biol. Markers 2011; 26: 173-180. http://dx.doi.org/10.5301/JBM.2011.8551
11. GOODELL MA, BROSE K, PARADIS G, CONNER AS, MULLIGAN RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med 1996; 183: 1797-1806. http://dx.doi.org/10.1084/ jem.183.4.1797
12. SZOTEK PP, CHANG HL, BRENNAND K, FUJINO A, PIERETTI-VANMARCKE R et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc. Natl. Acad. Sci. USA 2008; 105: 12469-12473. http://dx.doi.org/10.1073/pnas.0805012105
13. WU C, ALMAN BA. Side population cells in human cancers. Cancer Lett. 2008; 268: 1-9. http://dx.doi.org/10.1016/ j.canlet.2008.03.048
14. MATHEW G, TIMM EA Jr, SOTOMAYOR P, GODOY A, MONTECINOS VP et al. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009; 8: 1053-1061. http://dx.doi.org/10.4161/cc.8.7.8043
15. STROBEL T, SWANSON L, CANNISTRA SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997; 57: 1228-1232.
16. BERGAN L, GROSS JA, NEVIN B, URBAN N, SCHOLLER N. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett. 2007; 255: 263-274. http://dx.doi.org/10.1016/j.canlet.2007.04.012
17. Zavesky L, Jancarkova N, Kohoutova M. Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 2011; 58: 457-468. http://dx.doi:10.4149/neo_2011_06_457
18. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10: R25. http://dx.doi:10.1186/bcr1982
19. Hatina J, Schulz WA. Cancer stem cells-basic concepts. In: Encyclopedia of Life Sciences. Chichester: John Wiley & Sons, 2008. http://dx.doi.org/10.1002/9780470015902.a0021164
20. PERREN TJ, SWART AM, PFISTERER J, LEDERMANN JA, PUJADE-LAURAINE E et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484-2496. http://dx.doi.org/10.1056/NEJMoa1103799
21. BURGER RA, BRADY MF, BOOKMAN MA, FLEMING GF, MONK BJ et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011; 365: 2473-2483. http://dx.doi.org/10.1056/NEJMoa1104390
22. YANG ZJ, WECHSLER-REYA RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007; 11, 3-5. http://dx.doi.org/10.1016/j.ccr.2006.12.007
23. FUKAYA R, OHTA S, YAMAGUCHI M, FUJII H, KAWAKAMI Y et al.: Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett. 2010; 291: 150-157. http://dx.doi.org/10.1016/j.canlet.2009.10.010
24. NING ZF, HUANG YJ, LIN TX, ZHOU YX, JIANG C et al. Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res 2009; 37: 621-630.
25. CHIBA T, KITA K, ZHENG YW, YOKOSUKA O, SAISHO H et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251. http://dx.doi.org/10.1002/hep.21227
26. INCE TA, RICHARDSON AL, BELL GW, SAITOH M, GODAR S et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007; 12: 160-170. http://dx.doi.org/10.1016/j.ccr.2007.06.013
27. LIU T, CHENG W, LAI D, HUANG Y, GUO L. Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep. 2010; 23: 1277-1284.
28. ZEIMET AG, MARTH C, OFFNER FA, OBRIST P, UHLSTEIDL M et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol. Oncol. 1996; 62: 384-389. http://dx.doi.org/10.1006/gyno.1996.0253
29. WU YJ, PARKER LM, BINDER NE, BECKETT MA, SINARD JH et al. The mesothelial keratins: a new familiy of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell 1982; 31: 693-703. http://dx.doi.org/10.1016/0092-8674(82)90324-5
30. YIN G, CHEN R, ALVERO AB, FU HH, HOLMBERG J et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010; 29: 3545-3553. http://dx.doi.org/10.1038/onc.2010.111
31. STEFFENSEN KD, ALVERO AB, YANG Y, WALDSTRØM M, HUI P et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J. Oncol. 2011; 2011: 620523.
32. KRYCZEK I, LIU S, ROH M, VATAN L, SZELIGA W et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 2012; 130: 29-39. http://dx.doi.org/10.1002/ijc.25967
33. SILVA IA, BAI S, McLEAN K, YANG K, GRIFFITH K et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011; 71: 3991-4001. http://dx.doi.org/10.1158/0008-5472.CAN-10-3175
34. LANDEN CN Jr, GOODMAN B, KATRE AA, STEG AD, NICK AM et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 2010; 12: 3186-3199. http://dx.doi.org/10.1158/1535-7163.MCT-10-0563
35. STEWART DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007; 63: 12-31. http://dx.doi.org/10.1016/j.critrevonc.2007.02.001
36. ROSELL R, TARON M, BAMADAS A, SCAGLIOTTI G, SARRIES C et al. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10: 297-305.
37. WEBERPALS J, GARBUIO K, O'BRIEN A, CLARK-KNOWLES K, DOUCETTE S et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int. J. Cancer 2009; 124: 806-815. http://dx.doi.org/10.1002/ijc.23987
38. HATINA J, REIMER D, SOPPER S, BOESCH M, MARTOWICZ A, et al. Tumor stem cells and the biology of chemoresistance in ovarian cancer. (in German) Geburtsh Frauenheilk 2012; 72: 9 (Abstract - XXI. Wissenschaftliche Tagung der Arbeitsgemeinschaft für Gynekologische Onkologie, Salzburg 2012).
39. MORRISON SJ, KIMBLE J. Asymmetric and symmetric stemcell divisions in development and cancer. Nature 2006; 441: 1068-1074. http://dx.doi.org/10.1038/nature04956